Fibrinogen to albumin ratio in new acute leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at two simple blood test markers (fibrinogen and albumin) to see if their ratio can help predict outcomes in people with newly diagnosed acute leukemia. It is a no-treatment study — just a blood draw at diagnosis to gather information.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with acute leukemia.
- You have not yet received any treatment for your leukemia.
- You do not have a chronic inflammatory disease (like rheumatoid arthritis or inflammatory bowel disease) that could affect blood markers.
- You do not currently have a serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how a simple blood test (CRP to Albumin ratio) relates to blood clotting problems in people newly diagnosed with Acute Myeloid Leukemia (AML). The goal is to better understand how the disease affects your body and find ways to monitor your health.
This study looks at whether the ratio of platelets to white blood cells in your blood can help predict how acute myeloid leukemia (AML) will progress. The results from simple blood tests may offer clues about your disease and guide treatment decisions.
This study looks at a new score (SiAML) to predict bleeding and blood clot risks in people newly diagnosed with acute leukemia. It aims to help doctors better manage these risks compared to current tests.
This study looks at simple blood test results from people newly diagnosed with acute lymphoblastic leukemia (ALL) to see if certain markers help understand the disease better.
This study looks at markers in the blood to understand why low red blood cell counts (anemia) can cause bleeding problems in people with certain leukemias. It may help find better ways to treat or prevent bleeding during early chemotherapy.
This study measures two simple blood markers (SII and CAR) in people newly diagnosed with acute lymphoblastic leukemia (ALL) who haven't started treatment yet. The goal is to see if these markers can help guide care.
Hear when a new Patients with Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.